Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04557735
Other study ID # ALXN1210-TMA-314
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 7, 2020
Est. completion date May 30, 2025

Study information

Verified date June 2024
Source Alexion Pharmaceuticals, Inc.
Contact Alexion Pharmaceuticals, Inc. (Sponsor)
Phone 1-855-752-2356
Email clinicaltrials@alexion.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date May 30, 2025
Est. primary completion date November 29, 2024
Accepts healthy volunteers No
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria: 1. 1 month of age up to < 18 years of age at the time of signing the informed consent. 2. Received HSCT within the past 12 months. 3. Diagnosis of TMA that persists despite initial management of any triggering condition. 4. Body weight = 5 kilograms. 5. Female participants of childbearing potential and male participants with female partners of childbearing potential must use highly effective contraception starting at Screening and continuing until at least 8 months after the last dose of ravulizumab. 6. Participants must be vaccinated against meningococcal infections if clinically feasible, according to institutional guidelines for immune reconstitution after HSCT. Participants must be re-vaccinated against Haemophilus influenzae type b and Streptococcus pneumoniae if clinically feasible, according to institutional guidelines for immune reconstitution after HSCT. All participants should be administered coverage with prophylactic antibiotics according to institutional post-transplant infection prophylaxis guidances, including coverage against Neisseria meningitidis for at least 2 weeks after meningococcal vaccination. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis coverage against Neisseria meningitidis the entire Treatment Period and for 8 months following the final dose of ravulizumab. Exclusion Criteria: 1. Known familial or acquired 'a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13' deficiency (activity < 5%). 2. Known Shiga toxin-related hemolytic uremic syndrome. 3. Positive direct Coombs test. 4. Diagnosis or suspicion of disseminated intravascular coagulation. 5. Known bone marrow/graft failure. 6. Diagnosis of veno-occlusive disease (VOD). 7. Human immunodeficiency virus (HIV) infection (evidenced by HIV-1 or HIV-2 antibody titer). 8. Unresolved meningococcal disease. 9. Presence of sepsis requiring vasopressor support. 10. Pregnancy or breastfeeding. 11. Hypersensitivity to murine proteins or to 1 of the excipients of Ravulizumab. 12. Previously or currently treated with a complement inhibitor.

Study Design


Intervention

Drug:
Ravulizumab
Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.
Other:
Best Supportive Care
Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).

Locations

Country Name City State
France Research Site BRON Cedex
France Research Site Nantes cedex 01
France Research Site Paris
France Research Site Paris
France Research Site Strasbourg Cedex 2
France Research Site Vandoeuvre-Les-Nancy
Germany Research Site Berlin
Germany Research Site Freiburg
Germany Research Site Halle (Saale)
Germany Research Site Tuebingen
Germany Research Site Wuerzburg
Israel Research Site Haifa
Israel Research Site Jerusalem
Israel Research Site Petach-Tikva
Israel Research Site Ramat Gan
Italy Research Site Bologna
Italy Research Site Brescia
Italy Research Site Firenze
Italy Research Site Genova
Italy Research Site Monza
Italy Research Site Pavia
Italy Research Site Roma
Italy Research Site Roma
Italy Research Site Torino
Italy Research Site Verona
Japan Research Site Fukuoka-shi
Japan Research Site Fukushima-shi
Japan Research Site Kobe-shi
Japan Research Site Nagoya-shi
Japan Research Site Osaka-shi
Japan Research Site Osakasayama
Japan Research Site Saitama-Shi
Japan Research Site Setagaya-ku
Korea, Republic of Research Site Goyang-si
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Spain Research Site Barcelona
Spain Research Site Barcelona
Spain Research Site Esplugues de Llobregat
Spain Research Site Madrid
Spain Research Site Salamanca
Spain Research Site Valencia
United Kingdom Research Site Birmingham
United Kingdom Research Site Bristol
United Kingdom Research Site Leeds
United Kingdom Research Site London
United Kingdom Research Site Newcastle Upon Tyne
United States Research Site Akron Ohio
United States Research Site Atlanta Georgia
United States Research Site Aurora Colorado
United States Research Site Birmingham Alabama
United States Research Site Charlotte North Carolina
United States Research Site Chicago Illinois
United States Research Site Cleveland Ohio
United States Research Site Dallas Texas
United States Research Site Duarte California
United States Research Site Fort Worth Texas
United States Research Site Louisville Kentucky
United States Research Site Madison Wisconsin
United States Research Site Minneapolis Minnesota
United States Research Site Phoenix Arizona
United States Research Site Portland Oregon
United States Research Site Salt Lake City Utah
United States Research Site San Francisco California
United States Research Site Tucson Arizona
United States Research Site Valhalla New York

Sponsors (1)

Lead Sponsor Collaborator
Alexion Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  France,  Germany,  Israel,  Italy,  Japan,  Korea, Republic of,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary TMA Response 26 weeks (treatment period)
Secondary Time To TMA Response 26 weeks (treatment period)
Secondary TMA Relapse Follow Up period (183-365 Days after start of study medication)
Secondary Overall Survival 26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)
Secondary Hematologic Response Hematologic Response as assessed by blood tests to measure lactate dehydrogenase (LDH) and platelet count.
If baseline platelet count = 50,000/mm3, all of the following criteria must be met:
- Absolute platelet count > 50,000/mm3 without platelet transfusion support during the prior 7 days [or]
If baseline platelet count > 50,000/mm3, all of the following criteria must be met:
- = 50% increase in platelet count compared to baseline value
Normalization of LDH and absence of schistocytes
26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)
Secondary Proportion of Participants with Platelet Response = 100,000/mm^3 without transfusion support 26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)
Secondary Number of Participants with a Change from Baseline in TMA-associated Organ Dysfunction in Renal System, Cardiovascular System, Pulmonary System, CNS, and GI System. 26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)]
Secondary Proportion of Participants who die due to any cause during the study, with the exception of death due to underlying disease progression or relapse 26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)
See also
  Status Clinical Trial Phase
Completed NCT02604420 - Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Terminated NCT04743804 - Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger Phase 3
Recruiting NCT04845022 - Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome
Terminated NCT00593229 - International Registry and Biorepository for TMA(Thrombotic Microangiopathy) N/A
Recruiting NCT05991245 - French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
Terminated NCT00726544 - Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy Phase 2
Recruiting NCT04543591 - Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant Phase 3
Available NCT02355782 - OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy N/A